Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Raised to $260 at RBC Capital, 'Deep Dive Suggests Upcoming Liti SLE Data Could Start I&I Buildout On Right Path'

August 25, 2026 6:36 AM
RBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $260.00 (from $240.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change